Roche Holding AG (RHHBY)
| Market Cap | 318.88B +12.7% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | 20.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 19.63 |
| Forward PE | 15.74 |
| Dividend | 1.00 (2.01%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 325,150 |
| Average Volume | 2,513,818 |
| Open | 49.71 |
| Previous Close | 50.40 |
| Day's Range | 49.42 - 50.01 |
| 52-Week Range | 34.75 - 60.85 |
| Beta | 0.21 |
| RSI | 41.77 |
| Earnings Date | Apr 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Swiss industry body says US tariffs on pharmaceuticals will harm patients
U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, supply chains and ultimately will harm patients, Switzerland's pharmaceutical association interph...
Drugmakers face 100% tariff unless they cut prices or produce drugs in US
The Trump administration said on Thursday it will impose 100% tariffs on branded pharmaceuticals imported into the United States unless manufacturers agree to government drug pricing deals or commit ...
Global pharma companies that have publicly announced Trump drug pricing agreements
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-ye...
The Zacks Analyst Blog Roche Holding, AT&T and Amgen
AMGN, T, and Roche shares outperform as strong drug portfolios and wireless momentum offset key headwinds like pricing pressure and legacy declines.
Top Stock Reports for Roche, AT&T & Amgen
Roche's strong drug growth is offsetting legacy declines, while strategic deals aim to reshape its portfolio amid biosimilar pressure and FX headwinds.
Roche Announces Launch Of Cobas MPX-E Assay
(RTTNews) - Roche (RO.SW, ROG.SW) announced that the cobas MPX-E assay, a qualitative in-vitro test for the detection and discrimination of Human Immunodeficiency Virus and Hepatitis C, B, and E virus...
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply
Basel, 30 March 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the cobas® MPX-E assay, a qualitative in-vitro test for the detection and discrimination of Human Immunodeficiency Virus ...
Vector Institute Extends Collaboration With Roche
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Today, the Vector Institute announced the renewal of its collaboration with Roche through 2030, extending a connection that has advanced artificial intellig...
Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets
The new test detects up to 250 viruses and bacteria, including SARS-CoV-2, influenza, Bordetella pertussis , and RSV, in a single patient sample. Rapid results enable doctors to make fast, confident a...
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
Basel, 23 March 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the inauguration of the new research home for the Institute of Human Biology. The opening marks a significant milestone in Roc...
Roche Halts Development of Drug Candidate for Muscle Diseases, Chugai Says
The company discontinued developing emugrobart after two studies showed the drug didn't achieve intended outcomes.
Roche (RHHBY) Continues Obesity Trials Despite Neuromuscular Setbacks
Roche (RHHBY) Continues Obesity Trials Despite Neuromuscular Setbacks
Roche Bets Splits in Obesity Market Will Open Door to New Entrants
EXCLUSIVE: The pharmaceutical giant is re-entering the obesity market and aims to become a top-three player, rivaling the likes of Eli Lilly and Novo Nordisk.
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation
Roche's Ionify® steroid assays join its Vitamin D Total test as the latest mass spectrometry tests to receive CLIA 'moderate complexity' classification. The expanded steroid menu brings the sensitivit...
Mankind Pharma acquires Rivotril brand for India, reinforcing focus on chronic CNS therapies
Mankind Pharma Limited has announced its acquisition of the Rivotril brand from Roche for the Indian market. This acquisition grants Mankind Pharma exclusive rights to manufacture, market, and distrib...
Roche Expands AI Power With NVIDIA Blackwell GPUs
(RTTNews) - Roche announced a major expansion of its global AI infrastructure, unveiling the pharmaceutical industry's largest hybrid-cloud AI factory. With the addition of 2,176 NVIDIA Blackwell GPUs...
Roche (RHHBY) Expands AI Capabilities with Nvidia Partnership
Roche (RHHBY) Expands AI Capabilities with Nvidia Partnership
Roche Bought Thousands Of Nvidia AI Chips To Speed Up Drug Development
Pharmaceutical giant Roche said today it is launching a new large-scale “AI factory” with thousands of the latest Nvidia chips to accelerate the development of new drugs and diagnostics.
Roche ramps up AI computing capacity with Nvidia chip expansion
Swiss drugmaker Roche said on Monday it had expanded its artificial intelligence computing capacity with more than 2,100 Nvidia chips to support drug and diagnostics development.
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
Basel, 16 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that an expansion of its global AI infrastructure, deploying a large-scale AI factory powered by a full stack of the latest-ge...
Roche Secures CE Mark For First Blood Test To Identify ApoE4 Carriers In Alzheimer's Disease
(RTTNews) - Roche (RHHBY) has received CE Mark approval for the Elecsys ApoE4 test, the first in-vitro diagnostic immunoassay that can identify carriers of the ApoE4 genetic variant using a simple blo...
Roche (RHHBY) Gains CE Mark for Alzheimer's Biomarker Test
Roche (RHHBY) Gains CE Mark for Alzheimer's Biomarker Test